dbACP: A Comprehensive Database of Anti-Cancer Peptides

233 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp06639 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 64.15 µg/mL
dbacp06640 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 44.76 µg/mL
dbacp06641 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 110.59 µg/mL
dbacp06642 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 67.34 µg/mL
dbacp06643 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.75 µg/mL
dbacp06644 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 10.38 µg/mL
dbacp06645 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 50.72 µg/mL
dbacp06646 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 58.63 µg/mL
dbacp06647 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 160.62 µg/mL
dbacp06648 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 66.43 µg/mL
dbacp06649 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.22 µg/ mL
dbacp06650 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 12.63 µg/mL
dbacp06777 BK-1 rRP-Hyp-G-Thi-S-Apc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06778 BK-2 rRP-Hyp-G-Thi-S-f-Apc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06779 BK-3 Aaa-rRP-Hyp-G-Thi-S-Acc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06780 BK-4 Aaa-rRP-Hyp-G-Thi-S-f-Acc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06781 BK-5 rRP-Hyp-G-Thi-S-f-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06782 BK-6 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06783 BK-7 rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06784 BK-8 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06785 NT-9 RRPYIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06786 NT-10 RRPAIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06787 NT-11 RRPYAL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06788 NT-12 PEGRKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06789 NT-12 PEGKRPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06790 NT-12 PEGKKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06803 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 46.2 ± 7.6 μM
dbacp06804 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.3 ± 0.2 μM
dbacp06805 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 36.2 ± 2.8 μM
dbacp06806 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 29.0 ± 3.7 μM
dbacp06807 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 6.4 ± 0.6 μM
dbacp06808 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 33.3 ±7.4μM
dbacp06809 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 26.5 ± 2.4 μM
dbacp06810 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 μM
dbacp06811 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 20.9 ± 1.4 μM
dbacp06812 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.2 ± 1.9 μM
dbacp06813 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.3 ± 0.1 μM
dbacp06814 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 15.7 ±1.1μM
dbacp06815 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 22.5 ± 3.3 μM
dbacp06816 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 3.0 ± 0.1 μM
dbacp06817 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 51.5 ± 3.9 μM
dbacp06818 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 3.9 ± 0.2 μM
dbacp06819 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 51.0 ± 4.6 μM
dbacp06820 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 4.6 ± 0.2 μM
dbacp06821 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06822 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 37.5 ± 3.3 μM
dbacp06823 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.4 ± 0.2 μM
dbacp06824 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 38.5 ± 4.8 μM
dbacp06825 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 19.5 ± 0.5 μM
dbacp06826 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 μM
dbacp06827 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 44.2 ± 2.2μM
dbacp06828 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.7 ± 0.7 μM
dbacp06829 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.1 ± 0.2 μM
dbacp06830 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 9.0 ± 1.1μM
dbacp06831 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 > 64 μM
dbacp06832 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 10.3 ± 1.1 μM
dbacp06833 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06834 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 48.4 ± 0.7 μM
dbacp06835 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 11.5 ± 0.6 μM
dbacp06836 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HL-60 Leukemia Cancer CC50 = 34.1 ± 3.9 μM
dbacp06837 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay CRL-1739 Gastric Cancer CC50 = 31.6 ± 1.3 μM
dbacp06838 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 5.4 ± 0.3 μM
dbacp06839 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 41.0 ± 4.2 μM
dbacp06840 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.1 ± 1.4 μM
dbacp06841 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay K-562 Leukemia Cancer CC50 = 3.9 ± 0.1 μM
dbacp06871 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06872 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 67 µM
dbacp06873 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 122 µM
dbacp06874 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 95 µM
dbacp06875 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 68 µM
dbacp06876 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 = 73 µM
dbacp06877 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 105 µM
dbacp06878 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 170 µM
dbacp06879 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06880 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06881 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 130 µM
dbacp06882 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MDA-MB-231 Breast Cancer IC50 > 150 µM
dbacp06913 AC-P19M FAKKLAKLKKKLAKLAKKR Synthetic analogue of AC-P19 Inhibition of cell signalling WST-8 assay A-549 Lung Cancer IC50 = 9.84 µM
dbacp06914 AC-P19M FAKKLAKLKKKLAKLAKKR Synthetic analogue of AC-P19 Inhibition of cell signalling WST-8 assay H-460 Lung Cancer IC50 = 6.29 µM
dbacp07668 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.66 ± 0.0007 µg/ml
dbacp07669 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.45 ± 0.0042 µg/ml
dbacp07670 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.29% Cell death at 100 µg/ml
dbacp07671 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 83.02% Cell death at 100 µg/ml
dbacp07672 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.2 ± 0.007 µg/ml
dbacp07673 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.4 ± 0.0028 µg/ml
dbacp07674 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 69.73% Cell death at 100 µg/ml
dbacp07675 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 71.5% Cell death at 100 µg/ml
dbacp07676 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.76 ± 0.0035 µg/ml
dbacp07677 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.33 ± 0 µg/ml
dbacp07678 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.37% Cell death at 100 µg/ml
dbacp07679 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.47% Cell death at 100 µg/ml
dbacp07687 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.67 ± 0.0007 µg/ml
dbacp07688 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.12 ± 0.0042 µg/ml
dbacp07689 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.02% Cell death at 100 µg/ml
dbacp07690 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 82.36% Cell death at 100 µg/ml
dbacp07691 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.46 ± 0.0028 µg/ml
dbacp07692 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.92 ± 0.0021 µg/ml
dbacp07693 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.69% Cell death at 100 µg/ml
dbacp07694 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.38% Cell death at 100 µg/ml
dbacp07695 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.0007 µg/ml
dbacp07696 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.4 ± 0 µg/ml
dbacp07697 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07698 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 87.56% Cell death at 100 µg/ml
dbacp07699 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.5 ± 0.0056 µg/ml
dbacp07700 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.28 ± 0.0063 µg/ml
dbacp07701 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 56.72% Cell death at 100 µg/ml
dbacp07702 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 28.51% Cell death at 100 µg/ml
dbacp07703 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.53 ± 0.0014 µg/ml
dbacp07704 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.78 ± 0.0021 µg/ml
dbacp07705 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.13% Cell death at 100 µg/ml
dbacp07706 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 75.91% Cell death at 100 µg/ml
dbacp07707 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.007 µg/ml
dbacp07708 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.33 ± 0.0035 µg/ml
dbacp07709 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.1% Cell death at 100 µg/ml
dbacp07710 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.49% Cell death at 100 µg/ml
dbacp07711 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.99 ± 0.0014 µg/ml
dbacp07712 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.97 ± 0.0049 µg/ml
dbacp07713 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07714 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 91.52% Cell death at 100 µg/ml
dbacp07715 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.45 ± 0.0056 µg/ml
dbacp07716 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.98 ± 0.4256 µg/ml
dbacp07717 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 41.37% Cell death at 100 µg/ml
dbacp07718 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 97.74% Cell death at 100 µg/ml
dbacp07719 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.98 ± 0.0014 µg/ml
dbacp07720 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.31 ± 0.0063 µg/ml
dbacp07721 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 38.64% Cell death at 100 µg/ml
dbacp07722 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 49.33% Cell death at 100 µg/ml
dbacp07723 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 17.34 ± 0.0014 µg/ml
dbacp07724 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.2 ± 0.0021 µg/ml
dbacp07725 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 51.79% Cell death at 100 µg/ml
dbacp07726 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 27.61% Cell death at 100 µg/ml
dbacp07727 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.6 ± 0.0007 µg/ml
dbacp07728 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.78 ± 0.0212 µg/ml
dbacp07729 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07730 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 84.17% Cell death at 100 µg/ml
dbacp07731 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.21 ± 0.0056 µg/ml
dbacp07732 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.11 ± 0.0035 µg/ml
dbacp07733 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 47.68% Cell death at 100 µg/ml
dbacp07734 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 22.86% Cell death at 100 µg/ml
dbacp07735 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.35 ± 0.0014 µg/ml
dbacp07736 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.88 ± 0.0014 µg/ml
dbacp07737 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.35% Cell death at 100 µg/ml
dbacp07738 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.01% Cell death at 100 µg/ml
dbacp07739 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.12 ± 0.0007 µg/ml
dbacp07740 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.67 ± 0.0028 µg/ml
dbacp07741 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 36.85% Cell death at 100 µg/ml
dbacp07742 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 29.87% Cell death at 100 µg/ml
dbacp07743 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07744 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.44 ± 0.5536 µg/ml
dbacp07745 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.74% Cell death at 100 µg/ml
dbacp07746 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 1.59% Cell death at 100 µg/ml
dbacp07747 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.67 ± 0 µg/ml
dbacp07748 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.7 ± 0.0056 µg/ml
dbacp07749 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 73.98% Cell death at 100 µg/ml
dbacp07750 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 76.25% Cell death at 100 µg/ml
dbacp07751 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.5 ± 0.0014 µg/ml
dbacp07752 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.5 ± 0.0007 µg/ml
dbacp07753 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07754 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 92.09% Cell death at 100 µg/ml
dbacp07755 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.28 ± 0 µg/ml
dbacp07756 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.56 ± 0.0028 µg/ml
dbacp07757 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07758 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 71.27% Cell death at 100 µg/ml
dbacp07759 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.56 ± 0.0021 µg/ml
dbacp07760 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.67 ± 0.0014 µg/ml
dbacp07761 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.28% Cell death at 100 µg/ml
dbacp07762 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.47% Cell death at 100 µg/ml
dbacp07763 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.36 ± 0 µg/ml
dbacp07764 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.61 ± 0.0007 µg/ml
dbacp07765 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07766 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 74.89% Cell death at 100 µg/ml
dbacp07767 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.32 ± 0.0014 µg/ml
dbacp07768 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 14.2 ± 0.0014 µg/ml
dbacp07769 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 12.06% Cell death at 100 µg/ml
dbacp07770 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 81.34% Cell death at 100 µg/ml
dbacp07771 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.37 ± 0.0014 µg/ml
dbacp07772 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 13.2 ± 0 µg/ml
dbacp07773 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 63.84% Cell death at 100 µg/ml
dbacp07774 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 52.72% Cell death at 100 µg/ml
dbacp07775 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0 µg/ml
dbacp07776 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.23 ± 0.0007 µg/ml
dbacp07777 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 52.33% Cell death at 100 µg/ml
dbacp07778 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 27.43% Cell death at 100 µg/ml
dbacp07779 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.1 ± 0.0007 µg/ml
dbacp07780 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 12.11 ± 0.0056 µg/ml
dbacp07781 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.76% Cell death at 100 µg/ml
dbacp07782 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 88.24% Cell death at 100 µg/ml
dbacp07783 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.1 ± 0.0007 µg/ml
dbacp07784 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.4 ± 0.0028 µg/ml
dbacp07785 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 42.33% Cell death at 100 µg/ml
dbacp07786 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 29.87% Cell death at 100 µg/ml
dbacp07787 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07788 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.33 ± 0.0035 µg/ml
dbacp07789 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.54% Cell death at 100 µg/ml
dbacp07790 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 75.68% Cell death at 100 µg/ml
dbacp07791 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.4 ± 0.0014 µg/ml
dbacp07792 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 11.2 ± 0.0007 µg/ml
dbacp07793 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 74.53% Cell death at 100 µg/ml
dbacp07794 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 76.14% Cell death at 100 µg/ml
dbacp07795 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0.0007 µg/ml
dbacp07796 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 10.2 ± 0.0014 µg/ml
dbacp07797 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.55% Cell death at 100 µg/ml
dbacp07798 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer 56.51% Cell death at 100 µg/ml
dbacp07799 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.68 ± 0.0014 µg/ml
dbacp07800 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colorectal Cancer IC50 = 9.06 ± 0.0014 µg/ml
dbacp07801 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 46.58% Cell death at 100 µg/ml
dbacp07802 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HT-29 Colon Cancer 22.8% Cell death at 100 µg/ml
dbacp07951 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay PC-3 Prostate Cancer IC50 = 792.60 µM
dbacp07952 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay H-157 Lung Cancer IC50 = 58.18 µM
dbacp07953 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MDA-MB-435S Skin Cancer IC50 = 179.00 µM
dbacp07954 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay U-251-MG Brain Tumor IC50 = 278.30 µM
dbacp07955 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MCF-7 Breast Cancer IC50 = 316.90 µM
dbacp07993 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 16.2 ± 2.2 µM
dbacp07994 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 = 22.7 ± 0.86 µM
dbacp07995 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 =24.3 ± 0.8 µM
dbacp07996 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.85 ± 1.85 µM
dbacp07997 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp07998 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp07999 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 17.9 ± 1.1 µM
dbacp08000 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08001 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08002 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 =22.4 ± 2.2 µM
dbacp08003 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08004 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08005 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 29.5 ± 6.03 µM
dbacp08006 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08007 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 = 37.3 ± 3.5 µM
dbacp08008 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.33 ± 5.8 µM
dbacp08009 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08010 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM
dbacp08011 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 21.3 ± 1.13 µM
dbacp08012 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08013 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay NCI-H-460 Lung Cancer IC50 >100 µM